XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.3
Financial Royalty Assets, net - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2017
Nov. 30, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
May 31, 2025
Jan. 31, 2025
Dec. 31, 2024
Aug. 31, 2024
Jul. 15, 2024
Mar. 31, 2024
Sep. 18, 2023
Finite-Lived Intangible Assets                          
Impairment loss of financial royalty assets     $ 0   $ 0 $ 26,491,000              
Gross carrying value     221,704,000   221,704,000       $ 198,587,000        
Ohtuvayre inventors                          
Finite-Lived Intangible Assets                          
Gross carrying value               $ 1,800,000   $ 13,600,000   $ 3,800,000  
APEIRON                          
Finite-Lived Intangible Assets                          
Contract assets (financial royalty assets)       $ 106,156,000   106,156,000         $ 106,156,000    
Deferred tax liability                     18,109,000    
Tolerance Therapeutics (Tzield®)                          
Finite-Lived Intangible Assets                          
Cash payments for acquisition   $ 20,000,000                      
Product royalty (as a percent)   1.00%                      
Deferred tax liability                 5,500,000        
Ovid Therapeutics                          
Finite-Lived Intangible Assets                          
Impairment loss of financial royalty assets           26,200,000              
Selexis                          
Finite-Lived Intangible Assets                          
Impairment loss of financial royalty assets           300,000              
Elutia (CorMatrix)                          
Finite-Lived Intangible Assets                          
Product royalty (as a percent) 5.00%                        
Gross carrying value     8,466,000   8,466,000       9,418,000        
Proceeds from royalties received $ 10,000,000                        
Proceeds from common stock in lieu of cash payment             $ 2,300,000            
Credit loss adjustment     200,000 $ 300,000 1,000,000 $ 4,900,000              
Elutia (CorMatrix) | Maximum                          
Finite-Lived Intangible Assets                          
Additional royalties receivable under sales-based milestones $ 10,000,000                        
Qarziba                          
Finite-Lived Intangible Assets                          
Gross carrying value     $ 112,052,000   $ 112,052,000       $ 105,329,000        
Qarziba | APEIRON                          
Finite-Lived Intangible Assets                          
Contract assets (financial royalty assets)                     104,900,000    
Primrose mRNA                          
Finite-Lived Intangible Assets                          
Cash consideration paid                         $ 15,000,000
Percentage of milestones (as a percent)     50.00%   50.00%                
Others | APEIRON                          
Finite-Lived Intangible Assets                          
Contract assets (financial royalty assets)                     $ 1,300,000